These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22282490)

  • 1. When a little aspirin may be enough.
    Kastritis E; Dimopoulos MA
    Blood; 2012 Jan; 119(4):905-6. PubMed ID: 22282490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
    Niesvizky R; Martínez-Baños D; Jalbrzikowski J; Christos P; Furst J; De Sancho M; Mark T; Pearse R; Mazumdar M; Zafar F; Pekle K; Leonard J; Jayabalan D; Coleman M
    Leuk Lymphoma; 2007 Dec; 48(12):2330-7. PubMed ID: 18067007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
    Al-Ani F; Bermejo JM; Mateos MV; Louzada M
    Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of thrombosis with lenalidomide and its prevention with aspirin.
    Hirsh J
    Chest; 2007 Jan; 131(1):275-7. PubMed ID: 17218586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.
    Maharaj S; Chang S; Seegobin K; Serrano-Santiago I; Zuberi L
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):585-591. PubMed ID: 28508703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?].
    de Moreuil C; Ianotto JC; Eveillard JR; Carrier M; Delluc A
    Rev Med Interne; 2016 Jul; 37(7):473-9. PubMed ID: 26833146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide: an update on evidence from clinical trials.
    Dimopoulos MA; Terpos E
    Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
    Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD; Lim ABM; Suzuki K; Kosugi H; Grigoriadis G; Avivi I; Facon T; Jagannath S; Lonial S; Ghori RU; Farooqui MZH; Marinello P; San-Miguel J;
    Lancet Haematol; 2019 Sep; 6(9):e448-e458. PubMed ID: 31327689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma.
    Osafehinti D; Zivari K
    Case Rep Hematol; 2019; 2019():5180424. PubMed ID: 31885953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.
    Isoda A; Sato N; Miyazawa Y; Matsumoto Y; Koumoto M; Ookawa M; Sawamura M; Matsumoto M
    Int J Hematol; 2015 Sep; 102(3):271-7. PubMed ID: 26177588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
    Alexander M; Teoh KC; Lingaratnam S; Kirsa S; Mellor JD
    Asia Pac J Clin Oncol; 2013 Jun; 9(2):169-75. PubMed ID: 22998589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
    Bagratuni T; Kastritis E; Politou M; Roussou M; Kostouros E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanelias N; Terpos E; Dimopoulos MA
    Am J Hematol; 2013 Sep; 88(9):765-70. PubMed ID: 23757261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
    Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
    Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents.
    Calafiore V; Giamporcaro S; Conticello C; Romano A; Parisi M; Giuffrida G; Tibullo D; Di Raimondo F; Signorelli SS
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.
    Zagouri F; Roussou M; Kastritis E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Kalapanida D; Christoulas D; Migkou M; Terpos E; Dimopoulos MA
    Leuk Lymphoma; 2016 Aug; 57(8):1776-80. PubMed ID: 26916452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
    Yee AJ; Bensinger WI; Supko JG; Voorhees PM; Berdeja JG; Richardson PG; Libby EN; Wallace EE; Birrer NE; Burke JN; Tamang DL; Yang M; Jones SS; Wheeler CA; Markelewicz RJ; Raje NS
    Lancet Oncol; 2016 Nov; 17(11):1569-1578. PubMed ID: 27646843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.